Selected article for: "pneumococcal pneumonia and rifampicin treatment"

Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial
  • Document date: 2019_5_18
  • ID: 19ueli6e_19
    Snippet: In this exploratory study, the primary outcome was the feasibility of adding rifampicin to b-lactam antibiotics in the treatment of community-acquired pneumococcal pneumonia and the difference in LTA release between patients treated in the intervention group versus the ones in the control group. Secondary outcome variables were LTA-mediated inflammatory response, clinical response, MLPA results and inflammatory biomarkers. Laboratory procedures t.....
    Document: In this exploratory study, the primary outcome was the feasibility of adding rifampicin to b-lactam antibiotics in the treatment of community-acquired pneumococcal pneumonia and the difference in LTA release between patients treated in the intervention group versus the ones in the control group. Secondary outcome variables were LTA-mediated inflammatory response, clinical response, MLPA results and inflammatory biomarkers. Laboratory procedures to determine LTA response and LTA-mediated inflammatory response are described in the Supplementary data available at JAC Online.

    Search related documents:
    Co phrase search for related documents
    • clinical response and control group one: 1, 2
    • clinical response and exploratory study: 1, 2, 3, 4
    • clinical response and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical response and intervention group: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • clinical response and laboratory procedure: 1
    • clinical response and lta release: 1, 2
    • community acquire and inflammatory response: 1
    • control group and exploratory study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • control group and inflammatory biomarker: 1
    • control group and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control group and intervention group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control group and intervention group treat: 1, 2
    • control group and laboratory procedure: 1
    • control group one and inflammatory response: 1, 2, 3, 4, 5
    • control group one and intervention group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • exploratory study and inflammatory biomarker: 1
    • exploratory study and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • exploratory study and intervention group: 1, 2, 3, 4, 5, 6, 7, 8
    • inflammatory response and intervention group: 1, 2, 3, 4, 5, 6, 7